{"editorial":{"content_id":"6bda6209-fc4b-4c54-92b8-81c997a61b60","slug":"pague-menos-20261106-1ff874","content_type":"news","title":"Pague Menos三季度净利润增19.5%，同店销售增速放缓至5.6%","summary":"巴西连锁药店Pague Menos公布2026年三季度业绩，调整后净利润9630万雷亚尔、同比增长19.5%，但同店销售增速由二季度的8%放缓至5.6%。","body":"巴西连锁药店Pague Menos公布2026年第三季度业绩：调整后净利润9630万雷亚尔，同比增长19.5%；毛收入44亿雷亚尔，增长6.9%；调整后EBITDA为2.788亿雷亚尔，增长7.2%，利润率6.3%。\n\nBTG Pactual分析师指出，按IFRS 16前口径并剔除一次性项目计算，该利润较其预估高出10%。\n\n同店销售增长5.6%，低于第二季度的8%。据BTG分析，放缓主要反映GLP-1药物贡献减少以及OTC产品销售走弱，后者仅增长2.2%。GLP-1占收入比重达8.5%；司美格鲁肽类似版本上市后，其销量在第一至第三季度间增长209%，而平均价格下跌54%。\n\n现金流方面，经营性现金流达1.648亿雷亚尔，为2025年三季度的三倍以上；杠杆率降至EBITDA的1.8倍，低于一年前的2.5倍。\n\nPague Menos首席执行官若纳斯·马克斯（Jonas Marques）表示，三季度业绩反映了公司增长战略与财务纪律的一致性，并称即便面对更具挑战的市场环境，公司在盈利能力、现金创造以及数字渠道和客户关系方面仍在推进。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["企业动态","金融","行业趋势","br-health"],"content_level":"编辑整理","event_type":"公司动态","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-11-06T11:05:57.495Z","display_date":"2026-11-06","source_published_at":null,"source_url":"https://panoramafarmaceutico.com.br/pague-menos-amplia-lucro-mas-vendas-desaceleram/","source_name":"Panorama Farmacêutico","source_language":"pt","author_name":"编辑部","risk_level":"medium","risk_flags":[],"opportunity_flags":[],"trend_signals":[]},"intelligence":null,"meta":{"canonical_url":"https://chinabrazilinsight.com/news/pague-menos-20261106-1ff874","api_url":"https://chinabrazilinsight.com/api/public/content/pague-menos-20261106-1ff874","markdown_url":"https://chinabrazilinsight.com/api/public/content/pague-menos-20261106-1ff874?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/pague-menos-20261106-1ff874?view=json","last_updated":"2026-11-06T11:06:20.423Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}